Premium
Preventive effect of risedronate on bone loss in men receiving androgen‐deprivation therapy for prostate cancer
Author(s) -
Ishizaka Kazuhiro,
Machida Tatsuya,
Kobayashi Shuichiro,
Kanbe Naoko,
Kitahara Satoshi,
Yoshida KenIchiro
Publication year - 2007
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2007.01911.x
Subject(s) - medicine , bone mineral , androgen deprivation therapy , prostate cancer , n terminal telopeptide , femoral neck , bone resorption , urology , osteoporosis , endocrinology , bone density , bone remodeling , cancer , osteocalcin , biochemistry , chemistry , alkaline phosphatase , enzyme
Aim: Androgen‐deprivation therapy for prostate cancer decreases bone mineral density and increases the risk of fracture. The effect of risedronate, a potent third‐generation oral bisphosphonate, on bone loss during androgen deprivation therapy was investigated. Methods: Sixty‐one prostate cancer patients with a mean age (±SD) of 79 ± 6 years who had received androgen deprivation therapy for 42 ± 29 months were enrolled, and were treated with 2.5 mg of risedronate daily for six months. Bone mineral density was measured at the femoral neck, lumbar spine, and ultradistal radius by dual energy X‐ray absorptiometry. The percent change of bone mineral density after treatment with risedronate was calculated as the primary efficacy variable. Urinary N‐telopeptide of type I collagen was measured as a bone resorption marker. Results: Bone mineral density remained stable in the femoral neck and radius during risedronate therapy. In contrast, the bone mineral density of the lumbar spine showed a significant increase from 1069 ± 488 mg/cm 2 −1112 ± 497 mg/cm 2 ( P < 0.001), representing a gain of 4.9 ± 8.9%. Urinary N‐telopeptide of type I collagen decreased significantly ( P < 0.001) after three months of risedronate treatment. Conclusions: Risedronate could prevent and reverse bone loss in men receiving androgen deprivation therapy for prostate cancer by inhibiting bone resorption.